Skip to main content

Table 3 Hazard ratios (HRs) of all-cause mortality and mortality due to expanded and non-expanded CVD-related causes according to clinical stage of time-dependent annual mean eGFR stratified by proteinuria status (n=6,523)

From: Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: The Taichung Diabetes Study

 

HR (95% CI)

 

Without proteinuria (n=4,266)

Proteinuria (N=2,257)

Variables

n

All-cause mortality

Expanded CVD-related mortality

Non-expanded CVD-related mortality

n

All-cause mortality

Expanded CVD-related mortality

Non-expanded CVD-related mortality

Age-adjusted

        

Annual mean eGFR (mL/min/1.73m2)

      

 ≥90

2787

-

-

-

899

-

  

 60~89

1225

1.02 (0.75-1.39)

1.16 (0.72-1.86)

0.93 (0.62-1.40)

756

1.42 (1.03-1.96)*

1.62 (0.97-2.71)

1.31 (0.86-2.00)

 15~59

254

2.22 (1.56-3.18)***

2.20 (1.26-3.83)**

2.28 (1.43-3.63)***

602

2.51 (1.86-3.39)***

3.36 (2.11-5.37)***

1.99 (1.34-2.96)***

P for trend

 

<0.001

0.01

0.009

 

<0.001

<0.001

<0.001

Multivariate-adjusted1

       

Annual mean eGFR (mL/min/1.73m2)

      

 ≥90

2787

-

-

-

899

-

  

 60~89

1225

1.13 (0.82-1.54)

1.33 (0.82-2.16)

1.00 (0.66-1.52)

756

1.56 (1.12-2.16)**

1.76 (1.05-2.95)*

1.45 (0.94-2.22)

 15~59

254

2.46 (1.69-3.57)***

2.62 (1.47-4.70)**

2.39 (1.46-3.89)***

602

2.58 (1.90-3.51)***

3.28 (2.04-5.29)***

2.14 (1.42-3.22)***

P for trend

 

<0.001

0.003

0.005

 

<0.001

<0.001

<0.001

Multivariate-adjusted2

       

Annual mean eGFR (mL/min/1.73m2)

      

 ≥90

2787

-

-

-

899

-

-

-

 60~89

1225

1.11 (0.81-1.52)

1.28 (0.79-2.08)

1.01 (0.67-1.53)

756

1.53 (1.10-2.12)*

1.70 (1.02-2.86)*

1.43 (0.94-2.20)

 15~59

254

2.23 (1.51-3.30)***

1.98 (1.06-3.69)*

2.47 (1.49-4.10)***

602

2.49 (1.83-3.39)***

3.15 (1.96-5.09)***

2.06(1.37-3.12)***

P for trend

 

<0.001

0.04

0.006

 

<0.001

<0.001

<0.001

  1. Multivariate-adjusted1 age, duration of diabetes, smoking, alcohol drinking, exercising, hypertension, hypertension drug treatment, obesity, hyperlipidemia and type of DM treatment and HbA1C. Multivariate-adjusted2 DKA, HHNK, severe hypoglycemia, stroke, myocardial infarction, peripheral neuropathy, intermittent claudication and neuropathy in addition to variables in model 1.
  2. *:p<0.05; **:p<0.01; ***:p<0.001.